以结局为导向的[177Lu]Lu-PSMA-617放射配体治疗剂量学优化:单时间点剂量学优化的概念验证
本研究回顾性分析50例接受[177Lu]Lu-PSMA-617治疗的mCRPC患者,比较多次时间点(MTP)与单时间点(STP)剂量学,并基于治疗结局(TEAE和PSA反应)确定Hänscheid近似的最佳时间点。结果显示骨髓STP剂量学与贫血分级显著相关,且与MTP相关性无显著差异;PSA反应与累积剂量相关,STP与MTP间无显著差异。结论认为基于结局的STP时间点选择在给药后2天内与基于物理的选择一致。
要点
- 骨髓STP剂量学与贫血分级显著相关,且与MTP相关性强度无显著差异。
- PSA反应与MTP累积剂量和STP累积剂量均显著相关,两者间无显著差异。
- 基于结局选择的最佳STP时间点在给药后2天内与基于物理的选择一致。
核心结论
- 基于结局的Hänscheid STP剂量学时间点选择在给药后2天内与基于物理的选择一致,可作为剂量学发展的补充策略并促进临床转化。
研究设计与样本
- 回顾性分析50例接受[177Lu]Lu-PSMA-617 RPT的mCRPC患者的临床与影像数据,比较MTP与STP剂量学。
主要发现
- 骨髓STP剂量学与贫血分级显著相关(1d-STPDtox:Spearman's ρ=0.35;2d-STPDtox:ρ=0.41;3d-STPDtox:ρ=0.46;所有padj<0.001),与MTPDtox(ρ=0.43,p<0.001)一致。
- Williams' F检验证实各时间点STPDtox与MTPDtox导出的相关性强度无显著差异。
- PSA反应与MTPDcum(Spearman's ρ=-0.26,padj<0.05)及STPDcum(1d-&2d-STPDcum:ρ=-0.34,padj<0.001)均显著相关,STPDcum与MTPDcum导出的相关性无统计学显著差异。
临床怎么用
- 基于结局的STP剂量学可在给药后2天内选择时间点,与物理优化选择一致,可能简化临床剂量学实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Internal dosimetry in radiopharmaceutical therapy (RPT) traditionally prioritizes methodological optimization driven by physical dose accuracy. However, even recommended multiple-time-point (MTP) dosimetry remains subject to uncertainties related to limited sampling schedules, pharmacokinetic, and curve-fitting modeling assumptions. In patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-PSMA-617 RPT, we explored an outcome-driven dosimetry optimization strategy by comparing MTP and single-time-point (STP) dosimetry, and identifying optimal time-points (TPs) for Hänscheid approximation based on therapy outcomes. METHODS: Clinical and image data from 50 patients were retrospectively analyzed. Transient treatment-emergent adverse events (TEAEs) and prostate-specific antigen (PSA) response were monitored following CTCAE v5.0 and PCWG3. Cycle-level mean absorbed doses (MTPDtox, and 1d-, 2d-, 3d-STPDtox based on single SPECT acquisitions at 1-, 2-, 3-day(s) p.i.) were computed for organs-at-risk and whole-body tumors. Additionally, cumulative absorbed doses (STPDcum & MTPDcum) were derived for whole-body tumors. RESULTS: Bone marrow STP dosimetry correlated significantly with anaemia grading (1d-STPDtox: Spearman's ρ=0.35;2d-STPDtox: Spearman's ρ=0.41; 3d-STPDtox: Spearman's ρ=0.46; all padj<0.001), aligning with MTPDtox (Spearman's ρ=0.43, p<0.001). Williams' F-test confirmed no significant difference in correlation strength between STPDtox & MTPDtox derived correlations at any TPs. For PSA response, both MTPDcum (Spearman's ρ=-0.26, padj<0.05) and STPDcum (1d-&2d-STPDcum: Spearman's ρ=-0.34, padj<0.001) showed significant correlations, without statistically significant differences between STPDcum & MTPDcum derived correlations. CONCLUSION: The outcome-driven TP selection for Hänscheid-based STP dosimetry converges with the physics-based choice within 2-day p.i., the clinically driven approach offers an alternative and complementary strategy for dosimetry development and may facilitate its translation into clinical practice.
引用
- Hu J, Seifert R, Gomes CV, et al. Outcome-driven dosimetry optimization for [177Lu]Lu-PSMA-617 radiopharmaceutical therapy: proof of concept on single time point dosimetry optimization. Eur J Nucl Med Mol Imaging. 2026. PMID: 42287389. doi:10.1007/s00259-026-07936-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。